New drug tested for tough blood cancers that resist treatment

NCT ID NCT05397496

Summary

This is a first-in-human study to find a safe dose and schedule for an experimental drug called PIT565. It is for adults with advanced B-cell non-Hodgkin lymphoma or B-cell acute lymphoblastic leukemia that has returned or not responded to at least two prior treatments. The main goal is to understand the drug's safety and side effects before testing if it can help control these cancers.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA (B-NHL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Cancer Ctr

    New York, New York, 10065, United States

  • Novartis Investigative Site

    Ghent, 9000, Belgium

  • Novartis Investigative Site

    Beijing, 100730, China

  • Novartis Investigative Site

    Shanghai, 200032, China

  • Novartis Investigative Site

    Tianjin, 300020, China

  • Novartis Investigative Site

    Créteil, 94010, France

  • Novartis Investigative Site

    Marseille, 13273, France

  • Novartis Investigative Site

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    Reggio Emilia, RE, 42123, Italy

  • Novartis Investigative Site

    Kashiwa, Chiba, 2778577, Japan

  • Novartis Investigative Site

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    Singapore, 169608, Singapore

  • Novartis Investigative Site

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Oregon Health Sciences University

    Portland, Oregon, 97239, United States

  • The University of Kansas Clinical Research Ctr

    Fairway, Kansas, 66205, United States

  • University Of Miami

    Miami, Florida, 33136, United States

  • University of Chicago Medical Center

    Chicago, Illinois, 60637, United States

Conditions

Explore the condition pages connected to this study.